Targeting CCR5 for anti-HIV research

Area of Science:

• Immunology
• Virology
• Genetics

Background:

• Highly active antiretroviral therapy (HAART) manages human immunodeficiency virus (HIV) but does not eradicate it.
• C-C motif chemokine receptor 5 (CCR5) is a crucial co-receptor for HIV-1 entry, making it a key therapeutic target.
• Natural CCR5 genotypes, like CCR5 delta32, confer resistance to certain HIV strains.

Purpose of the Study:

• To summarize current anti-HIV research focused on C-C motif chemokine receptor 5 (CCR5).
• To review CCR5 antagonist development, stem cell transplantation, and gene therapy strategies for HIV treatment.

Main Methods:

• Review of CCR5 antagonist development, including approved drugs like maraviroc and those in clinical trials.
• Analysis of stem cell transplantation using CCR5 delta32 genotype donors, exemplified by the Berlin patient's cure.
• Examination of gene therapy approaches, such as zinc finger nuclease (ZFN)-modified CD4 T cells.

Main Results:

• CCR5 antagonists represent a significant therapeutic avenue, with maraviroc already approved.
• Stem cell transplantation from CCR5 delta32 donors has demonstrated the potential for HIV eradication.
• Gene therapy using engineered T cells shows promise for durable HIV control.

Conclusions:

• Targeting CCR5 offers diverse strategies for achieving a functional cure for HIV infection.
• Combining CCR5-based approaches with existing therapies may lead to novel treatment paradigms.
• Continued research in CCR5 antagonists, stem cell therapy, and gene editing is crucial for advancing HIV cure.